Amphiregulin Mediates Estrogen, Progesterone, and EGFR Signaling in the Normal Rat Mammary Gland and in Hormone-Dependent Rat Mammary Cancers
- 1.5k Downloads
Both estrogen (E) and progesterone (P) are implicated in the etiology of human breast cancer. Defining their mechanisms of action, particularly in vivo, is relevant to the prevention and therapy of breast cancer. We investigated the molecular and cellular mechanisms of E and/or P-induced in vivo proliferation, in the normal rat mammary gland and in hormone-dependent rat mammary cancers which share many characteristics with the normal human breast and hormone-dependent breast cancers. We show that E+P treatment induced significantly greater proliferation in both the normal gland and mammary cancers compared to E alone. In both the normal gland and tumors, E+P-induced proliferation was mediated through the increased production of amphiregulin (Areg), an epidermal growth factor receptor (EGFR) ligand, and the activation of intracellular signaling pathways (Erk, Akt, JNK) downstream of EGFR that regulate proliferation. In vitro experiments using rat primary mammary organoids or T47D breast cancer cells confirmed that Areg and the synthetic progestin, R5020, synergize to promote cell proliferation through EGFR signaling. Iressa, an EGFR inhibitor, effectively blocked this proliferation. These results indicate that mediators of cross talk between E, P, and EGFR pathways may be considered as relevant molecular targets for the therapy of hormone-dependent breast cancers, especially in premenopausal women.
KeywordsProgesterone Estradiol Progesterone receptor Amphiregulin EGFR Mammary gland Proliferation Mammary cancer
Estrogen (E) and progesterone (P) are implicated in the etiology of breast cancer [1, 2]. However, their precise cellular and molecular mechanisms of action in the breast, particularly in vivo, are not well understood. Determining how E and/or P contribute to proliferation is important for understanding their roles in the normal breast and in the etiology of breast cancer. While the role of E in breast cancer has been widely studied, less is known about the role of P. This is particularly relevant because, in postmenopausal women, hormonal therapy with estrogen plus progestin (compared to estrogen alone) significantly increases breast cancer risk .
P imparts its biological action via two major progesterone receptor (PR) isoforms, PRA and PRB. Numerous lines of evidence suggest that PRA and PRB have distinct physiological functions in vitro and in vivo. Experiments using stable monoclonal cell lines of T47D human breast cancer cells that are PR negative, express only PRA, or express only PRB, have shown that PR isoforms differ in their ability to activate gene transcription, to interact with cytoplasmic signaling cascades, and in their requirements for activation by ligand [3, 4, 5]. Studies in mice lacking or overexpressing PR isoforms in the mammary gland indicate that PRA may be involved in sidebranching, while PRB is critical for lobuloalveolar formation during pregnancy [6, 7, 8].
Studies in the T47D breast cancer cell line have demonstrated that P action is closely interconnected with epidermal growth factor receptor (EGFR) signaling [9, 10, 11]. PRB seems to be a critical mediator of the cross talk between P and EGFR pathways. P action via PRB but not PRA leads to an autocrine activation of EGFR that results in sustained phosphorylation of Erk . In turn, epidermal growth factor (EGF) treatment activates several intracellular signaling pathways downstream of EGFR that dramatically increase transcriptional activity of PRB both in the presence and absence of ligand [12, 13]. It is currently not known whether the cross talk between P and EGFR signaling takes place in the normal breast and primary mammary cancers in vivo.
Recent studies of PR isoform expression in the normal human breast have shown that the developmental pattern of PR isoform expression, PR isoform colocalization, and cell-type specific expression of PR isoforms are similar to those observed in the rat mammary gland . Both the human breast and rat mammary gland have a similar ductal-lobular organization [15, 16], and mammary cancers induced in the rat are predominantly hormone-dependent similar to the majority of human breast cancers. Therefore, studies on the mechanisms of P action in the normal rat mammary gland and hormone-dependent rat mammary cancers may provide insights into P action that are relevant to the human breast and breast cancer.
We report that E and P work together in vivo in cells co-expressing estrogen receptor α (ERα), PRA, and PRB to induce robust proliferation in both the normal mammary gland and hormone-dependent mammary cancers through the induction of amphiregulin (Areg). We propose that Areg acts as an autocrine/paracrine EGFR ligand to activate EGFR downstream signaling that, in concert with P acting through PRB, promotes proliferation in ERα+PRA+PRB+ and ERα−PRA−PRB+ cells. Furthermore, in vitro experiments showed that Iressa, an EGFR inhibitor, can effectively block this pathway and proliferation. The conserved cross talk between E, P, and EGFR signaling in mammary tumors suggests that combining EGFR inhibitors with antiestrogen therapy may prove beneficial in the treatment of hormone-dependent human breast cancers, in particular, in premenopausal women.
Normal Mammary Gland
Adult 18-week-old Sprague–Dawley rats (Charles-River Laboratory, Raleigh, NC, USA) were ovariectomized (OVX), and 2 weeks later, the animals were injected subcutaneously with vehicle control, E (17 μg/kg), P (15 mg/kg), or a combination of E+P (17 μg/kg + 15 mg/kg) daily for 3 days. Sham-operated, vehicle-treated rats served as ovary-intact control (OI). For Elvax pellet implant experiments, ovariectomized animals were implanted in the right inguinal mammary gland with an Elvax 40P (DuPont Inc.) pellet containing human recombinant Areg (Sigma, St. Louis, MO, USA) (10 μg Areg + 0.2 mg bovine serum albumin (BSA)/pellet); the contralateral inguinal gland was implanted with a control pellet containing only BSA (0.2 mg) as previously described . Control, E, or P injections daily for 3 days were initiated immediately after pellet implantation.
For mammary cancer development, ovariectomized 50-day-old rats were implanted with silastic pellets containing E (2.5 mg/1 cm) with or without four pellets releasing P (50 mg/4 cm) and treated with a single intragastric dose (50 mg/kg) of 7,12-dimethylbenz[α]anthracene. Normal mammary tissues and tumors were fixed in 10% buffered formalin and paraffin-embedded for immunohistochemical analysis or flash-frozen in liquid nitrogen and stored at −80°C for messenger RNA (mRNA) or protein analysis. For all experiments, animals were euthanized 2 h after i.p. injection with 5-bromo-2-deoxyuridine (BrdU) (Sigma) (70 mg/kg). All animal handling procedures were approved by the Michigan State University Committee on Animal Use and Care.
T47D cell lines, T47D-Y (lacking PR), T47D-YA (expressing only PRA), and T47D-YB (expressing only PRB) , were generously provided by Dr. KB Horwitz (University of Colorado). Cells were grown in minimal essential media and 5% fetal bovine serum as described . For experiments, cells were cultured in phenol red- and serum-free media for 24 h, treated with synthetic progestin R5020 (20 nM) with or without Iressa (gefitinib, ChemieTek, Indianapolis, IN, USA; 500 nM) or RU486 (mifepristone, Calbiochem, La Jolla, CA, USA; 100 nM) for 24 h, and then treated with 25 nM Areg for 30 min according to the published protocol for these cell lines .
Analysis of the Cell Cycle in T47D Cells
Cells were plated at density 6 × 105 cells/well in six-well plates in the presence of serum. Cells were cultured for 48 h in serum-free conditions, treated for 24 h, trypsinized, and fixed with 80% methanol. Cells were stained with 4′,6-diamidino-2-phenylindole (DAPI) (1 μg/ml) and analyzed with the BD Vantage Turbo SE flow cytometer and ModFit3.2 software.
Primary Culture of the Rat Mammary Organoids in Collagen Gel
Primary culture of mammary organoids in collagen gels was performed as described . Organoids were cultured in serum-free media containing 0.1% BSA and supplemented with 1× essential amino acids, 0.5× non-essential amino acids, 0.5× vitamins (Invitrogen, Carlsbad, CA, USA), 1× serum replacement 1 reagent, and 0.2× ITS (insulin-transferrin-sodium selenite) media from Sigma for 5 days. Organoids were treated with P (20nM), Areg (25 nM), or Areg+P. Proliferation was assessed by BrdU incorporation for the last 24 h of culture . Collagen gels were fixed in 10% buffered formalin, paraffin-embedded, and sectioned for immunohistochemical analysis.
The antibodies used in the study were mouse monoclonal anti-human PR antibody (hPRa7), PRA-specific in immunohistochemistry , and anti-human PRB (hPRa6), PRB-specific in immunoblot and immunohistochemistry (Neomarkers, CA, USA; dilution 1:100 and1:25, respectively) . Rabbit polyclonal anti-mouse PRB antibody (B15, custom-made by Affinity Bioreagents, Golden, CO, USA; 1:800) was used for immunohistochemistry. The B15 rabbit antibody was developed to specifically detect PRB in the mouse and rat that differs significantly from the human PRB in the B-specific N-terminal region and to reduce the issue of potential for cross-reactivity between two mouse monoclonal antibodies (hPRA6 and hPRA7) that detect human PRA and PRB. The B15 antibody has been shown previously to be specific for the detection of only PRB by immunohistochemistry and immunoblot in rat mammary tissue . Rabbit polyclonal anti-PR antibody (DAKO A0098, Carpinteria, CA, USA) detects both PRA and PRB by immunoblot. Rabbit polyclonal anti-α-smooth muscle actin (SMA) (1:200), mouse monoclonal anti-α-tubulin (1:400), anti-cytokeratin 18 (1:100) antibody (Abcam, Cambridge, MA, USA), rabbit polyclonal anti-phospho-Akt1/2/3 (Ser473) (1:75), anti-total Erk (1:200), goat polyclonal anti-β-actin (1:1,000) and anti-phospho-c-Jun (Ser73) (1:25), mouse monoclonal anti-c-Fos (1:50), anti-Areg (1:100), anti-phospho-Erk (Tyr204) (1:100), rabbit polyclonal anti-nuclear factor kappa B (NFκB) (p65) (1:50), antibody specific to phospho-serine (1:100) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit polyclonal anti-cyclin D1 (Biosource, Camarillo, CA, USA; 1:100), rabbit polyclonal anti-EGFR (1:100), mouse monoclonal anti-phospho-EGFR (Tyr1068) (1:100) (both from Cell Signaling, Beverly, MA, USA), goat polyclonal anti-Areg (R&D Systems, Minneapolis, MN, USA; 1:40), rabbit polyclonal anti-β-catenin, anti-keratin 18 (both from Sigma, St. Louis, MO, USA; 1:200), mouse monoclonal anti-proliferating cell nuclear antigen (PCNA) (Calbiochem, San Diego, CA, USA; 1:100), mouse monoclonal anti-ERα (6F11, Novocastra, UK; 1:10), and sheep polyclonal anti-BrdU antibody (Biodesign International, Saco, ME, USA; 1:25) were used in the experiments. AlexaFluor488, AlexaFluor546, or AlexaFluor633-labeled secondary antibodies against mouse, rabbit, sheep, or goat were purchased from Invitrogen, Eugene, OR, USA. Nuclei were counterstained with DAPI.
Immunoperoxidase staining, single, double, or triple immunofluorescent labeling were performed as described  with modification for the triple labeling where the combination of the mouse, rabbit, and goat or mouse, rabbit, and sheep primary antibodies were used. Images were captured with a Nikon inverted epi-fluorescence microscope or an Olympus Fluoview laser scanning confocal microscope (Mager Scientific, Dexter, MI, USA) and analyzed with MetaMorph software (Molecular Devices Corp., Downington, PA, USA).
Immunoblot and In-cell Western Analysis
For immunoblot analysis, samples were homogenized in radioimmunoprecipitation buffer (Santa Cruz Biotechnology) according to the manufacturer’s instructions and resolved on 4–20% NuPAGE gels (Invitrogen). To detect phospho-PRB, 600 μg of total protein was immunoprecipitated with a mixture of anti-PR antibodies (DAKO and hPRa7) and blotted onto nitrocellulose membrane. The membrane was incubated with phospho-serine specific antibody (primary mouse mAb and IRDye™800-labeled secondary antibody). This was followed by incubation with PRB-specific antibody (primary rabbit polyclonal B15, 1:500; IRDye™680-labeled secondary antibody). Using the Li-Cor Odyssey detection system allowed simultaneous detection of both antibodies. Colocalization of the two antibodies (anti-phospho-serine and anti-PRB) was used to measure the level of phospho-PRB. Fold change data were obtained by normalization of the band density to the density of α-tubulin, β-actin, keratin 18, or IgG band (in immunoprecipitation experiments), followed by normalization of obtained values to the value in the control group. For in-cell Western analysis, cells were gown in 96-well plates in triplicates, treated with Areg, R5020 with or without inhibitors as described above, fixed in 10% buffered formalin, and incubated with primary antibodies for phospho-Akt/tubulin or phospho-Erk/total Erk as described . Anti-mouse or anti-rabbit IRDye™680 or IRDye™800-labeled secondary antibody was purchased from Li-Cor Biosciences, Lincoln, NE, USA (dilution 1:4,000 for immunoblot; 1:500 for in-cell Western). Membranes and 96-well plates were scanned and analyzed with a Li-Cor Odyssey infrared scanner.
Total RNA was isolated using Trizol reagent (Invitrogen) according to the manufacturer’s instructions. Preparation of cDNA and real-time PCR analysis were performed as previously described . Expression levels of genes of interest were normalized to 18S expression . Primers specific for the rat EGF, epiregulin (Ereg), Epigen, Areg, betacellulin (Btc), TGFα, heparin-binding EGF-like growth factor, EGFR, receptor activator of nuclear factor kappa B ligand (RANKL), and Wnt4 were purchased from SA Biosciences, Frederick, MD, USA. Delta-Delta CT method was used to calculate changes in gene expression. Tests were performed on RNA isolated from a minimum of three animals or four tumors per experimental group with three technical replicates for each sample. For EGFR ligands, fold change was calculated compared to EGF expression level because it was the lowest expressed EGFR ligand in OVX control (threshold cycle ∼29).
Quantitation and Statistical Analysis
The number of BrdU+ cells detected by immunoperoxidase staining and the number of PRA, PRB, BrdU, or SMA+ cells, and colocalization of these markers detected by immunofluorescent labeling were quantitated as previously described . In mammary tissue sections, the percent of positive cells was determined for ducts and lobules. The number of positive cells was expressed as the percent of total epithelial cells counted. Results were presented as mean ± SEM and differences were considered significant at P < 0.05 by ANOVA/MANOVA with Duncan’s post hoc test where appropriate.
E and P Synergistically Induce Proliferation in Cells That Express PRB in the Normal Mammary Gland
Virtually all luminal cells expressing PRA also co-expressed ERα (Fig. 2e) and PRB (Fig. 2a–c). Thus, in OI glands, 98.0 ± 0.9% of ERα-positive (ERα+) cells co-expressed PRA and 93.9 ± 1.2% of PRA+ cells co-expressed ERα. In contrast, a significant population of PRB+ cells did not co-express PRA (Fig. 2a–c) or ERα (Fig. 2f). Based on these results, we conclude that there are two major populations of steroid receptor-positive luminal cells: cells that co-express ERα, PRA, and PRB and cells that express only PRB. As previously reported, myoepithelial cells that expressed only PRB were also detected (data not shown) . However, since ERα, PRA, and PRB were colocalized exclusively in luminal cells and luminal cells compose the bulk of hormone-dependent breast cancers, the following experiments have focused on P effects in the luminal cell compartment.
The majority of proliferating BrdU+ cells expressed only PRB (Fig. 2g). This was especially true for ducts in E-treated glands and for both ducts and lobules in E+P-treated glands. Only a smaller fraction of the proliferating cells co-expressed PRB, PRA, and ERα. Receptor-negative (ERα−/PR−) proliferating cells were rare in E-treated glands (4%). In contrast, in E+P-treated glands, there were significantly more proliferating receptor-negative cells.
E and P Regulate Expression of the Paracrine Growth Factor, Amphiregulin
As shown above, most proliferation occurred in cells expressing only PRB (Fig. 2g). Although PRB expression was maintained after OVX (Fig. 2a, b), E and P were both required to induce robust proliferation. This suggested that an E-induced paracrine factor(s) was required in addition to P for proliferation in cells expressing only PRB.
RANKL and Wnt4 have also been identified as paracrine mediators of P-induced proliferation in the mouse mammary gland [19, 27, 28, 29]. Therefore, we measured RANKL and Wnt4 mRNA levels and compared them with Areg mRNA expression (Supplemental Fig. 1). Both RANKL and Wnt4 were increased only in E+P and their levels were lower than Areg. Since we observed an induction of both paracrine factors by E+P treatment, we analyzed the expression pattern of their respective downstream signaling molecules, NFκB p65 and β-catenin [30, 31], by immunofluorescence. However, we found no noticeable changes in intracellular distribution or intensity of the staining for both NFκB p65 and β-catenin in E+P-treated glands compared to OVX control glands (data not shown). Based on these results, further experiments were focused on the role of Areg in mediating E+P-induced proliferation.
Areg and P Are Sufficient to Induce Proliferation After Ovariectomy In Vivo
E and P Increase EGFR Expression and Signaling in the Normal Mammary Gland In Vivo
Studies in T47D breast cancer cells have shown that EGF treatment induces Erk-dependent PRB phosphorylation on serine residues . Phosphorylated PRB is the transcriptionally more active form of the receptor . Consistent with findings in T47D human breast cancer cell line, an analysis of PRB phosphorylation in hormone-treated glands showed 1.9- and 2.4-fold increases in phospho-PRB after E and E+P treatments, respectively (Fig. 5e).
P and Areg Cooperate to Induce Proliferation in Primary Rat Mammary Organoids In Vitro
Progestin and Areg Cooperatively Induce Proliferation in T47D Breast Cancer Cells Expressing PRB
E + P Treatment Increases Proliferation in Hormone-Dependent Rat Mammary Cancers
E + P Treatment Leads to a Greater Activation of EGFR Pathway in Mammary Cancers Compared to E Treatment
We also analyzed expression of RANKL and Wnt4 in hormone-treated mammary tumors (Supplemental Fig. 2). Notably, Areg expression was by far greater than RANKL or Wnt4 mRNA expression in both E- and E+P-treated tumors.
In the present study, we investigated the molecular and cellular mechanisms underlying E and/or P-induced proliferation, in the rat normal mammary gland and in hormone-dependent rat mammary cancers. The rat was chosen for these studies because ERα, PRA, and PRB exhibit cell-type-specific localization remarkably similar to the adult premenopausal human breast. [14, 36]. Importantly, these studies were carried out in vivo and therefore may provide information relevant to in vivo P action in the human breast and breast cancer.
Hormonal Regulation of PR Isoform Expression and Proliferation in the Normal Gland
The rat mammary gland contains three populations of luminal epithelial cells: cells that co-express ERα, PRA, and PRB; cells that express only PRB; and cells that are ERα, PRA, and PRB negative. Cells expressing only PRB are also observed in the normal human premenopausal breast  and in the pregnant mouse mammary gland . As reported by others , we found that PRA expression was E dependent. In contrast, PRB expression was E and P independent being equally expressed in OVX and hormone-treated glands. This is consistent with the previous observation that only PRB is expressed prior to significant production of ovarian hormones in the pre-pubertal rat mammary gland . In the human breast, an overall reduction of PR expression has been shown after menopause  compared to the premenopausal breast , presumably due to reduced estrogen levels. However, it is not known whether PRA and PRB are differentially regulated after menopause.
In OVX rats, E+P treatment produced significantly greater proliferation than treatment with E alone. The majority of proliferation occurred in cells expressing only PRB or in cells that were ERα, PRA, and PRB negative. Multiple studies in the human breast and rodent mammary glands have reported that proliferation occurs mostly in ERα/PR-negative cells [37, 40, 41]. While our results may seem at odds with these previous reports, it is important to point out that many commercially available anti-PR antibodies detect only PRA and not PRB by immunohistochemistry . Thus, it is quite possible that previous reports failed to detect PRB in proliferating cells. Since a sub-population of cells that express only PRB are also ERα/PRA negative in the rat and human [14, 21], the proliferating PRB expressing cells in those studies would have been considered to be ERα, PR negative.
Areg, an Autocrine/Paracrine Mediator of P-Induced Proliferation
The requirement of both E and P for induction of robust proliferation despite abundant PRB expression after OVX led us to consider that an E-induced paracrine factor in addition to P was required for proliferation. Based on studies of E-induced Areg, an EGFR ligand in mouse mammary gland  and P action in T47D breast cancer cells, as well as the interaction of PR and EGFR, we investigated EGFR ligands as potential candidates of the E-induced paracrine factor. Within the 3-day time frame of hormone treatments herein, Areg was by far the most highly E-induced EGFR ligand in the rat mammary gland. The human Areg gene has a putative estrogen response element  and Areg expression is strongly induced by E in the human breast . Thus, E-induced Areg expression in the rat is consistent with findings in the human and mouse mammary glands. In the rat, despite the increased Areg mRNA levels induced by E, the highest level of Areg protein was observed only in E+P-treated glands and was detected in cells expressing ERα, PRA and PRB, but not in cells expressing only PRB. Differential regulation of Areg mRNA and protein has been previously observed in human eosinophils . Our findings indicate that P acting through PRA and/or PRB may stabilize or stimulate translation of Areg protein in the rat mammary gland.
That Areg, an E-induced paracrine factor, could replace E and act in concert with P to induce robust proliferation in vivo was demonstrated in the Elvax pellet implant experiments. The majority of proliferating cells expressed PRB. Likewise, in mammary organoids in vitro, the combination of Areg+P also dramatically increased proliferation. Notably, both PR and EGFR signaling were necessary for the proliferative response. Analysis of proliferation (percent of cells in S phase) in T47D cells expressing only PRB, also demonstrated that only Areg+R5020 increased proliferation compared to Areg or R5020 alone and could be inhibited by either Iressa or RU486. These results suggest that Areg acting through EGFR and P acting through PRB cooperate to induce proliferation.
P-dependent paracrine factors, RANKL and Wnt4, were also induced by E+P treatment in OVX glands. However, intra-cellular localization of their respective downstream targets, NFκB p65 and β-catenin, was not altered by E+P treatment. Thus, compared to Areg, it appears that under the current experimental conditions (OVX followed by 3 days of hormone treatment), RANKL and Wnt4 have a lesser effect on proliferation.
Interactions Between P, E, and EGFR Signaling
The E-dependent upregulation of EGFR protein expression that was observed in the normal gland likely enhances responsiveness to Areg. Areg binding to EGFR can activate Akt, JNK, and Erk [9, 33, 45]. We found that E+P treatment of the normal gland markedly activated not only Akt, a key regulator of cell proliferation and survival , but also c-Jun, a molecular target of JNK. Importantly, both phospho-Akt and phospho-c-Jun were detected in luminal epithelial cells, consistent with EGFR signaling occurring in the mammary epithelium.
Activation of JNK and Erk leads to formation of an activated AP-1 transcription complex (phospho-c-Jun/c-Fos heterodimer) important for cell proliferation . While c-Fos was equally increased by E or E+P treatment, phospho-c-Jun was increased only by E+P, suggesting that both E and P were required for activation of AP-1. In the mouse, the blockade of AP-1 function results in decreased proliferation, stunted mammary gland growth, and reduced sidebranching, suggesting a pivotal role for AP-1 in epithelial proliferation . E+P treatment also increased PCNA protein, a promoter of cell cycle progression. Interestingly, PCNA has been identified as a PRB-dependent gene in T47D breast cancer cells . We speculate that in the rat mammary gland PCNA transcription is also driven by liganded PRB.
Extensive cross talk between EGF and P signaling has been shown in T47D breast cancer cells [9, 10, 50]. EGF induces a transient phosphorylation of Ser294 in PRB in an Erk-dependent manner . This phosphorylation causes nuclear translocation of un-liganded PRB and renders PRB more sensitive to ligand . In this study, we found that PRB phosphorylation of serine residues was increased in vivo by E and further increased after E+P treatment in the normal gland. Thus, the observed phosphorylation of PRB is consistent with Areg production and activation of EGFR signaling in the epithelium and correlates with proliferation of cells expressing PRB. This suggests that phosphorylation of PRB may enhance the transcriptional activity of PRB in vivo.
Interaction Between P and Areg Is Mediated by PRB
Comparison of E, P, and the EGFR Signaling in the Normal Mammary Gland and Mammary Cancers in the Rat
The combination of E+P was more potent than E alone in promoting proliferation in both normal mammary glands and in mammary tumors that developed in hormone-treated rats. The proliferation rates elicited by E or E+P in tumors were not significantly different from those in normal glands. These results suggest that endogenous P in premenopausal women and exogenous P in combined estrogen+progestin hormonal therapy in postmenopausal women may also contribute to tumor proliferation.
The percent of cells co-expressing PRA and PRB was not significantly different between E and E+P-treated normal mammary glands. However, tumor development was notably associated with an increased percentage of cells expressing only PRA and a reduced percentage of cells expressing only PRB. Thus, altered PR isoform expression in tumors may lead to the increased P signaling via PRA. Predominance of PRA expression has been detected in early precancerous lesions of the human breast suggesting that increased PRA expression is an event associated with the early stages of cancer development . In breast cancers, the predominance of PRA expression is associated with a more aggressive tumor phenotype and worse prognosis for overall survival . Studies in human breast cancer cells have also demonstrated that PRA activates transcription of several genes that are associated with cell transformation and cell motility and may confer a more aggressive cellular phenotype . However, there is another possible mechanism to be considered to explain the observed reduced percentage of PRB positive cells and increased percentage of PRA positive cells in tumors from E+P-treated rats. This change could be the result of increased PRB phosphorylation and rapid receptor turnover leading to a lack of detection by immunohistochemistry. Rapid turnover of PRB is reported to be related to increased transcriptional activity in T47D human breast cancer cells expressing the PRB isoform in the presence of ligand . This could also explain the increased proliferation observed in tumors arising in E+P-treated rats.
Based on mRNA levels, relative EGFR levels were similar in E- and E+P-treated normal glands and tumors. Analysis of mRNA expression showed that Areg was the most highly expressed EGFR ligand in normal glands and highly expressed in tumors. It should be noted that Ereg levels were similar to Areg levels in tumors and therefore may contribute to proliferation in tumors. In the normal gland, Areg protein was highly induced only in the presence of E+P. However, in tumors, treatment with either E alone or E+P induced comparable levels of Areg protein. Interestingly, increased Areg protein was not detected in normal mammary cells adjacent to tumors (data not shown). This suggests that increased Areg expression was specifically associated with tumor development and not merely the result of the chronic hormone exposure.
Our results obtained in vivo in the normal rat gland, in rat primary mammary organoid cultures, and in T47D YB cells demonstrated that Areg signaling via EGFR cooperates with P signaling to promote proliferation. Consistent with this, we also observed a marked activation of signaling pathways downstream of EGFR in E+P-treated normal mammary glands and in E+P-treated tumors compared to treatment with E alone. However, it should be noted that there was significant variability among tumors in the two treatment groups. These results indicate that the interaction between P and EGFR signaling that drives proliferation in the normal mammary gland is similarly functional in a subset of tumors. The results in the rat mammary gland and mammary cancer suggest that Akt phosphorylation can serve as an indicator of ongoing P and EGFR cross talk. In T47D YB cells, Areg+R5020 increased phosphorylation of Erk to a greater extent than Akt. The difference between signaling inT47D cells and signaling in the normal rat mammary gland and tumors may be due to intrinsic species differences in EGFR signaling. It is also possible that dependence on Erk activation may be specific to T47D cells and does not necessarily reflect the features of all human primary hormone-dependent breast cancers. Despite this difference between rat mammary cancers and T47D breast cancer cells, the cross talk between E, P, and EGFR signaling (i.e., Areg production, Akt phosphorylation, Erk phosphorylation) may present important molecular markers and targets for the treatment of hormone-dependent mammary cancers that develop in premenopausal women. In this regard, inhibition of EGFR phosphorylation by Iressa blocked Areg+P-induced proliferation in primary mammary organoids and markedly inhibited Areg+P-induced Erk phosphorylation that was associated with proliferation in T47D-YB cells. Iressa has been shown to reduce mammary tumor incidence and cause tumor regression in carcinogen-treated rats . Furthermore, the combination of Iressa and an aromatase inhibitor was more effective than Iressa alone . Iressa is currently under investigation in clinical trials for the treatment of breast cancer patients. In a recent trial, Iressa treatment showed a better clinical benefit rate in chemotherapy-naive patients with hormone-dependent breast cancers than in patients with hormone-independent cancers . Our results that demonstrate E, P, and EGFR cross talk in hormone-dependent rat mammary cancers provide a plausible explanation for this clinical finding.
Progestins continue to be highly implicated in the etiology of human breast cancer . Recently RANKL, a P-induced paracrine factor, has been implicated in the development of mammary cancer in the mouse [57, 58]. In the rat (Kariagina and Haslam, unpublished observations) and mouse normal mammary gland , RANKL is produced only in cells that express PRA. It should be noted that rat and the mouse mammary glands differ with regard to developmental expression, hormonal regulation, and colocalization of PRA and PRB. In the mouse, PRA and PRB are generally expressed in different cells, PRA expression is significantly maintained after OVX , and RANKL can be induced by P alone . In the rat, virtually no PRA is detectable after OVX, and RANKL induction requires combined E+P treatment (Supplemental Fig. 1). In contrast to the mouse, the pattern of PRA and PRB expression and colocalization of both isoforms in the same cell in rat closely resembles the pattern observed in the human breast [14, 21]. The majority of carcinogen-induced mammary tumors in the rat are ER+PR+ and hormone dependent in contrast to mouse mammary cancer models which are predominantly ER−PR− and hormone independent. Furthermore, E-treated rats develop mammary cancer in the absence of RANKL expression (Supplemental Fig. 2). This raises the possibility that Areg may be a more relevant E+P-induced mediator of the development of hormone-dependent human breast cancer. While a role of RANKL has not yet been identified in the development of hormone-dependent mammary cancer in the rat, its potential role in tumor cell proliferation and tumor behavior warrants further investigation.
In conclusion, the present study demonstrates that E and P interact with EGFR signaling through Areg to induce proliferation in the normal mammary tissue and hormone-dependent mammary cancer. Inhibition of EGFR may be a promising therapeutic strategy to be used in combination with anti-hormone therapies for the treatment of hormone-dependent breast cancers that exhibit activation of EGFR signaling. This may be particularly relevant for premenopausal women who produce endogenous progesterone. The results obtained herein also indicate that the rat is a relevant model for testing therapeutic strategies that can block this signaling pathway.
The authors thank Jennifer Ward, Kristina Miller, Lyndsi Davenport, Kyle Pohl, Alicia Kramer, Sharmila Kulkarni, Bennett Cho, Howard Herr, and Jang Park for the excellent technical assistance and Dr. Louis King for the analysis of the cell cycle experiments. This work was supported by the U.S. Army Medical Research and Materiel Command under W81XWH-07-1-0502 (to S.Z.H) and by the Breast Cancer and the Environment Research Centers Grant U01 ES/CA 012800 (to S.Z.H.) from the National Institute of Environment Health Science (NIEHS) and the National Cancer Institute (NCI), National Institutes of Health, Department of Health and Human Services. The contents of the study are solely the responsibility of the authors and do not necessarily represent the official views of the NIEHS or NCI, NIH.
Conflict of interest
The authors declare that they have no conflict of interests.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
- 4.Tung L, Abdel-Hafiz H, Shen T, Harvell DM, Nitao LK, Richer JK, Sartorius CA, Takimoto GS, Horwitz KB (2006) Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B. Mol Endocrinol 20:2656–2670CrossRefPubMedGoogle Scholar
- 10.Daniel AR, Qiu M, Faivre EJ, Ostrander JH, Skildum A, Lange CA (2007) Linkage of progestin and epidermal growth factor signaling: phosphorylation of progesterone receptors mediates transcriptional hypersensitivity and increased ligand-independent breast cancer cell growth. Steroids 72:188–201CrossRefPubMedGoogle Scholar
- 18.Sartorius CA, Groshong SD, Miller LA, Powell RL, Tung L, Takimoto GS, Horwitz KB (1994) New T47D breast cancer cell lines for the independent study of progesterone B- and A-receptors: only antiprogestin-occupied B-receptors are switched to transcriptional agonists by cAMP. Cancer Res 54:3868–3877PubMedGoogle Scholar
- 32.Eckstein N, Servan K, Girard L, Cai D, von Jonquieres G, Jaehde U, Kassack MU, Gazdar AF, Minna JD, Royer HD (2008) Epidermal growth factor receptor pathway analysis identifies amphiregulin as a key factor for cisplatin resistance of human breast cancer cells. J Biol Chem 283:739–750CrossRefPubMedGoogle Scholar
- 39.Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ (1999) Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 84:4559–4565CrossRefPubMedGoogle Scholar
- 53.Shen T, Horwitz KB, Lange CA (2001) Transcriptional hyperactivity of human progesterone receptors is coupled to their ligand-dependent down-regulation by mitogen-activated protein kinase-dependent phosphorylation of serine 294. Mol Cell Biol 21:6122–6131Google Scholar
- 55.Ciardiello F, Troiani T, Caputo F, De Laurentiis M, Tortora G, Palmieri G, De Vita F, Diadema MR, Orditura M, Colantuoni G, Gridelli C, Catalano G, De Placido S, Bianco AR (2006) Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 94:1604–1609PubMedGoogle Scholar
- 56.Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304:1684–1692CrossRefPubMedGoogle Scholar
- 57.Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468:98–102CrossRefPubMedGoogle Scholar